Avadel pharmaceuticals announces publication of study data in advances in therapy highlighting need for once-at-bedtime oxybate dosing for narcolepsy

Among 100 clinicians, the primary driver of overall oxybate choice, potential to improve patient quality of life, and decrease stress/anxiety was a single bedtime dose over the twice-nightly dosing of first-generation oxybates among 100 clinicians, the primary driver of overall oxybate choice, potential to improve patient quality of life, and decrease stress/anxiety was a single bedtime dose over the twice-nightly dosing of first-generation oxybates
AVDL Ratings Summary
AVDL Quant Ranking